301239 普瑞眼科
已收盘 01-09 15:00:00
资讯
新帖
简况
每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训
证券之星 · 01-03
每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训
12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 2025-12-31
12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股
11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 2025-11-21
11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股
普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长
证券之星 · 2025-10-29
普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长
普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%
证券之星 · 2025-10-27
普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%
普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%
智通财经 · 2025-10-27
普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%
普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%
证券之星 · 2025-10-17
普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%
证券之星 · 2025-09-29
普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%
普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%
证券之星 · 2025-09-17
普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%
股市必读：普瑞眼科（301239）9月10日董秘有最新回复
证券之星 · 2025-09-11
股市必读：普瑞眼科（301239）9月10日董秘有最新回复
普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑
证券之星 · 2025-09-10
普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑
普瑞眼科（301239）2025年中报简析：增收不增利
证券之星 · 2025-08-30
普瑞眼科（301239）2025年中报简析：增收不增利
股市必读：普瑞眼科中报 - 第二季度单季净利润同比下降147.83%
证券之星 · 2025-08-29
股市必读：普瑞眼科中报 - 第二季度单季净利润同比下降147.83%
普瑞眼科(301239.SZ)发布上半年业绩，归母净利润1466.75万元，下降66.12%
智通财经 · 2025-08-28
普瑞眼科(301239.SZ)发布上半年业绩，归母净利润1466.75万元，下降66.12%
高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票
智通财经 · 2025-07-31
高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票
7月24日普瑞眼科涨5.02%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 2025-07-24
7月24日普瑞眼科涨5.02%，融通健康产业灵活配置混合A/B基金重仓该股
普瑞眼科涨5.02%，东吴证券二个月前给出“买入”评级
证券之星 · 2025-07-24
普瑞眼科涨5.02%，东吴证券二个月前给出“买入”评级
普瑞眼科：提升公司内在价值增强投资者信心
证券之星 · 2025-07-10
普瑞眼科：提升公司内在价值增强投资者信心
普瑞眼科（301239）7882.96万股限售股将于7月7日解禁，占总股本52.69%
证券之星 · 2025-07-07
普瑞眼科（301239）7882.96万股限售股将于7月7日解禁，占总股本52.69%
3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股
证券之星 · 2025-03-07
3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股
公司概况
公司名称：
普瑞眼科医院集团股份有限公司
所属行业：
卫生
上市日期：
2022-07-05
主营业务：
普瑞眼科医院集团股份有限公司的主营业务是为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。公司的主要产品是屈光手术、白内障、眼视光、眼底病、青光眼、斜视与小儿眼科、泪道、角膜病、眼眶病、眼外伤、医学验光配镜。
发行价格：
33.65
{"stockData":{"symbol":"301239","market":"SZ","secType":"STK","nameCN":"普瑞眼科","latestPrice":33.29,"timestamp":1767942219000,"preClose":32.95,"halted":0,"volume":1822500,"delay":0,"changeRate":0.0103,"floatShares":150000000,"shares":150000000,"eps":-0.6775,"marketStatus":"已收盘","change":0.34,"latestTime":"01-09 15:00:00","open":32.82,"high":33.45,"low":32.72,"amount":60266400,"amplitude":0.0222,"askPrice":33.29,"askSize":80,"bidPrice":33.28,"bidSize":42,"shortable":0,"etf":0,"ttmEps":-0.6775,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":32.95,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":36.25,"lowLimit":29.66,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":149619048,"isCdr":false,"pbRate":2.32,"roa":"--","roe":"0.77%","epsLYR":-0.68,"committee":-0.326425,"marketValue":4981000000,"turnoverRate":0.0122,"status":0,"floatMarketCap":4981000000},"requestUrl":"/m/hq/s/301239/wiki","defaultTab":"wiki","newsList":[{"id":"2600928067","title":"每周股票复盘：普瑞眼科（301239）开展2025年度持续督导培训","url":"https://stock-news.laohu8.com/highlight/detail?id=2600928067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600928067?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:50","pubTimestamp":1767379817,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，普瑞眼科报收于32.89元，较上周的31.22元上涨5.35%。本周，普瑞眼科12月31日盘中最高价报34.1元。12月30日盘中最低价报30.75元。普瑞眼科当前最新总市值49.21亿元，在医疗服务板块市值排名34/51，在两市A股市值排名3399/5181。公司公告汇总国泰海通证券股份有限公司作为普瑞眼科医院集团股份有限公司的保荐机构，于2025年12月22日以现场与线上相结合的方式开展了2025年度持续督导培训。公司对本次培训积极配合，达到了预期效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2595805721","title":"12月31日普瑞眼科涨6.23%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595805721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595805721?lang=zh_cn&edition=full","pubTime":"2025-12-31 15:36","pubTimestamp":1767166603,"startTime":"0","endTime":"0","summary":"证券之星消息，12月31日普瑞眼科涨6.23%，收盘报32.89元，换手率3.52%，成交量5.26万手，成交额1.73亿元。重仓普瑞眼科的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家；过去90天内机构目标均价为42.05。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100022392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2585190059","title":"11月21日普瑞眼科跌6.15%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190059?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:05","pubTimestamp":1763712311,"startTime":"0","endTime":"0","summary":"证券之星消息，11月21日普瑞眼科跌6.15%创60日新低，收盘报33.85元，换手率1.87%，成交量2.8万手，成交额9690.99万元。重仓普瑞眼科的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级2家，增持评级2家；过去90天内机构目标均价为48.4。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100019189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2579164679","title":"普瑞眼科（301239）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2579164679","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579164679?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:44","pubTimestamp":1761691481,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期普瑞眼科发布2025年三季报。根据财报显示，普瑞眼科营收净利润同比双双增长。截至本报告期末，公司营业总收入22.01亿元，同比上升2.99%，归母净利润1634.91万元，同比上升3.21%。按单季度数据看，第三季度营业总收入7.41亿元，同比上升3.48%，第三季度归母净利润168.17万元，同比上升106.13%。持有普瑞眼科最多的基金为融通健康产业灵活配置混合A/B，目前规模为18.16亿元，最新净值2.819，较上一交易日下跌0.04%，近一年上涨10.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900010963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239"],"gpt_icon":0},{"id":"2578164006","title":"普瑞眼科(301239)9月30日股东户数1.04万户，较上期减少1.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578164006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578164006?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:17","pubTimestamp":1761556638,"startTime":"0","endTime":"0","summary":"证券之星消息，近日普瑞眼科披露，截至2025年9月30日公司股东户数为1.04万户，较6月30日减少211.0户，减幅为1.98%。在医疗服务行业个股中，普瑞眼科股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.63万户。从股价来看，2025年6月30日至2025年9月30日，普瑞眼科区间跌幅为6.63%，在此期间股东户数减少211.0户，减幅为1.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700023664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2578618554","title":"普瑞眼科(301239.SZ)发布前三季度业绩，归母净利润1634.91万元，增长3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578618554","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578618554?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:10","pubTimestamp":1761552600,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普瑞眼科(301239.SZ)发布2025年三季度报告，该公司前三季度营业收入为22.01亿元，同比增长2.99%。归属于上市公司股东的净利润为1634.91万元，同比增长3.21%。归属于上市公司股东的扣除非经常性损益的净利润为2466.98万元，同比增长34.71%。基本每股收益为0.11元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301239"],"gpt_icon":0},{"id":"2576514900","title":"普瑞眼科（301239）披露董事会成员调整及换届选举议案，10月17日股价下跌1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576514900","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576514900?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:50","pubTimestamp":1760712626,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，普瑞眼科报收于36.31元，较前一交易日下跌1.14%，最新总市值为54.33亿元。该股当日开盘36.73元，最高36.88元，最低36.3元，成交额达3124.01万元，换手率为0.57%。上述选举议案均需提交股东会采用累积投票制表决。所有议案表决结果均为同意7票，反对0票，弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2571849483","title":"普瑞眼科（301239）股东成都普瑞世纪投资有限责任公司质押190万股，占总股本1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571849483","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571849483?lang=zh_cn&edition=full","pubTime":"2025-09-29 18:28","pubTimestamp":1759141709,"startTime":"0","endTime":"0","summary":"证券之星消息，普瑞眼科9月29日公开信息显示，股东成都普瑞世纪投资有限责任公司向杭州银行股份有限公司上海张江支行合计质押190.0万股，占总股本1.27%。质押详情见下表：截止本公告日，股东成都普瑞世纪投资有限责任公司已累计质押股份2494.12万股，占其持股总数的46.42%。普瑞眼科主营业务：致力于为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900028040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2568497680","title":"普瑞眼科（301239）发布2025年半年度持续督导跟踪报告，9月17日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568497680","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568497680?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:48","pubTimestamp":1758120497,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘，普瑞眼科报收于38.87元，较前一交易日下跌0.28%，最新总市值为58.16亿元。近日，国泰海通证券股份有限公司发布了关于普瑞眼科医院集团股份有限公司2025年半年度持续督导跟踪报告（报备）。公告显示，报告期内，保荐人及时审阅信息披露文件，公司信息披露规范，未发生未及时审阅情况。报告期内发表专项意见6次，无非同意意见，公司及相关股东均正常履行承诺事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2566348987","title":"股市必读：普瑞眼科（301239）9月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2566348987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566348987?lang=zh_cn&edition=full","pubTime":"2025-09-11 04:46","pubTimestamp":1757537172,"startTime":"0","endTime":"0","summary":"截至2025年9月10日收盘，普瑞眼科报收于38.1元，上涨0.32%，换手率1.04%，成交量1.56万手，成交额5948.98万元。董秘最新回复投资者： 公司一季度业绩有所好转，录得扣非净利润 2,831.55 万元，同比增长48.37%，经营活动现金流净额 1.95 亿元，同比增长 54.87%，整体呈现营收、利润、现金流协同增长的良好态势。当日关注点来自交易信息汇总：9月10日主力资金净流出48.2万元，游资积极介入，散户同步减持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091100003919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2566626006","title":"普瑞眼科：二季度受需求放缓及行业竞争影响业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2566626006","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566626006?lang=zh_cn&edition=full","pubTime":"2025-09-10 11:36","pubTimestamp":1757475412,"startTime":"0","endTime":"0","summary":"但半年报发布后，我们发现二季度业绩下滑明显，甚至抹去了一季度的部分利润。普瑞眼科回复：尊敬的投资者您好，2025年二季度受整体需求增长放缓及行业竞争加剧的双重影响，公司各业务板块的营收增长受到较大挑战，且白内障项目受人工晶体集中带量采购政策及医保DRG/DIP支付方式改革等影响，营业收入下降，故二季度整体业绩有所下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000015003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2563700950","title":"普瑞眼科（301239）2025年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2563700950","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563700950?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:36","pubTimestamp":1756507000,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期普瑞眼科发布2025年中报。根据财报显示，普瑞眼科增收不增利。截至本报告期末，公司营业总收入14.59亿元，同比上升2.74%，归母净利润1466.75万元，同比下降66.12%。本次财报公布的各项数据指标表现一般。持有普瑞眼科最多的基金为融通健康产业灵活配置混合A/B，目前规模为20.74亿元，最新净值2.925，较上一交易日上涨0.34%，近一年上涨43.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000012260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2563064353","title":"股市必读：普瑞眼科中报 - 第二季度单季净利润同比下降147.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563064353","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563064353?lang=zh_cn&edition=full","pubTime":"2025-08-29 05:27","pubTimestamp":1756416435,"startTime":"0","endTime":"0","summary":"截至2025年8月28日收盘，普瑞眼科报收于42.76元，下跌0.47%，换手率2.15%，成交量3.21万手，成交额1.36亿元。股本股东变化股东户数变动近日普瑞眼科披露，截至2025年6月30日公司股东户数为1.06万户，较3月31日增加625.0户，增幅为6.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900004604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239"],"gpt_icon":0},{"id":"2562321086","title":"普瑞眼科(301239.SZ)发布上半年业绩，归母净利润1466.75万元，下降66.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562321086","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562321086?lang=zh_cn&edition=full","pubTime":"2025-08-28 16:11","pubTimestamp":1756368702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普瑞眼科(301239.SZ)发布2025年半年度报告，该公司营业收入为14.59亿元，同比增长2.74%。归属于上市公司股东的净利润为1466.75万元，同比减少66.12%。归属于上市公司股东的扣除非经常性损益的净利润为2078.09万元，同比减少54.14%。基本每股收益为0.0985元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"普瑞眼科(301239.SZ)发布上半年业绩，归母净利润1466.75万元，下降66.12%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301239"],"gpt_icon":0},{"id":"2555003687","title":"高盛：“银发群体” 崛起带动高端自付治疗项目增长 关注其中受益的主要股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2555003687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555003687?lang=zh_cn&edition=full","pubTime":"2025-07-31 11:00","pubTimestamp":1753930843,"startTime":"0","endTime":"0","summary":"高盛重点列出了覆盖范围内最有望从高端自付治疗项目增长中受益的主要股票——上调爱尔眼科、智飞生物至“买入”评级、予普瑞眼科、Straumann“买入”评级、升通策医疗评级至“中性”。2024 年，该群体虽仅占50岁以上总人口的3%，却贡献了该群体医疗健康支出的5%，高盛预计到2035年，这一比例将增长至13%。高盛假设在2024-2035年期间，50岁以上、净资产超过300万元人民币的群体的医疗健康支出在基准/乐观/悲观情景下的复合年增长率分别为 14%/19%/9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111141094c52dd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0028","BK0048","BK0236","BK0239","BK0077","301239","300015","BK0113","BK0188","LU1242518931.SGD","LU1242518857.USD","BK0284","BK0012","LU1328615791.USD","LU0979878070.USD","LU2580892789.USD","BK0046","300122","BK0114","LU1146622755.USD","LU2148510915.USD","LU2580892862.HKD","BK0146","600763","BK0196","BK0200","LU1064131003.USD","BK0096","LU1820825898.SGD"],"gpt_icon":0},{"id":"2553270897","title":"7月24日普瑞眼科涨5.02%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553270897","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553270897?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:29","pubTimestamp":1753345774,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日普瑞眼科涨5.02%，收盘报42.87元，换手率3.59%，成交量5.38万手，成交额2.25亿元。重仓普瑞眼科的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为60.32。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。该公募基金现任基金经理为万民远。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400025044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2553270381","title":"普瑞眼科涨5.02%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2553270381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553270381?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:29","pubTimestamp":1753345768,"startTime":"0","endTime":"0","summary":"今日普瑞眼科（301239）涨5.02%，收盘报42.87元。2025年4月30日，东吴证券研究员朱国广,冉胜男,苏丰发布了对普瑞眼科的研报《2024年年报及2025年一季报点评：Q1业绩符合预期，新院爬坡有望带来业绩改善》，该研报对普瑞眼科给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为16.78%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华创证券的黄致君。普瑞眼科（301239）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072400025040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","601555"],"gpt_icon":0},{"id":"2550132826","title":"普瑞眼科：提升公司内在价值增强投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2550132826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550132826?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:03","pubTimestamp":1752131020,"startTime":"0","endTime":"0","summary":"证券之星消息，普瑞眼科07月10日在投资者关系平台上答复投资者关心的问题。公司管理层一直非常重视二级市场给投资者的回报，现已采取多种措施并制定了详细的计划来提升公司市值。未来将继续致力于提升公司内在价值，通过优化公司治理、完善信息披露、加强投资者关系管理等方式，增强投资者对公司发展的信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000018255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0236","301239"],"gpt_icon":0},{"id":"2549742093","title":"普瑞眼科（301239）7882.96万股限售股将于7月7日解禁，占总股本52.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549742093","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549742093?lang=zh_cn&edition=full","pubTime":"2025-07-07 08:02","pubTimestamp":1751846567,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，普瑞眼科于7月7日将有7882.96万股限售股份解禁，为公司首发原股东限售股份，占公司总股本52.69%。本次解禁后，公司已无限售股份。普瑞眼科主营业务：致力于为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700001533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301239","BK0236"],"gpt_icon":0},{"id":"2517170897","title":"3月7日普瑞眼科跌5.97%，广发高端制造股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517170897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517170897?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:25","pubTimestamp":1741335959,"startTime":"0","endTime":"0","summary":"证券之星消息，3月7日普瑞眼科跌5.97%，收盘报49.9元，换手率4.34%，成交量3.07万手，成交额1.56亿元。根据2024基金年报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为广发高端制造股票A。广发高端制造股票A目前规模为61.43亿元，最新净值1.2707，较上一交易日上涨0.89%，近一年下跌13.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030700026706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161037","BK0236","301239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767960516923,"stockEarnings":[{"period":"1week","weight":0.0018},{"period":"1month","weight":0.0058},{"period":"3month","weight":-0.1107},{"period":"6month","weight":-0.1707},{"period":"1year","weight":-0.1922},{"period":"ytd","weight":0.0018}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.264},{"period":"ytd","weight":0.0288}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普瑞眼科医院集团股份有限公司","boardCode":"AI0083","boardName":"卫生","stockholders":"10438人(较上一季度减少1.98%)","perCapita":"14334股","listingDate":"2022-07-05","address":"四川省成都市金牛区一环路北四段215号","registeredCapital":"14961万元","survey":" 普瑞眼科医院集团股份有限公司的主营业务是为眼科疾病患者提供诊断、治疗、保健及医学验光配镜等眼科全科医疗服务。公司的主要产品是屈光手术、白内障、眼视光、眼底病、青光眼、斜视与小儿眼科、泪道、角膜病、眼眶病、眼外伤、医学验光配镜。","listedPrice":33.65},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普瑞眼科(301239)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普瑞眼科(301239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普瑞眼科,301239,普瑞眼科股票,普瑞眼科股票老虎,普瑞眼科股票老虎国际,普瑞眼科行情,普瑞眼科股票行情,普瑞眼科股价,普瑞眼科股市,普瑞眼科股票价格,普瑞眼科股票交易,普瑞眼科股票购买,普瑞眼科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普瑞眼科(301239)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普瑞眼科(301239)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}